Internationally recognized as a leading regional full-service contract research organization (CRO), Novotech is proud to be sponsoring this upcoming webinar interview and panel discussion on "Expedited Clinical Development Strategies for China".
We welcome you to join us for
Since 2015’s progressive regulatory reform and with the current focus on growth and innovation, China’s regulatory and clinical trial environment offers an attractive clinical development pathway solution for Western Biotech companies.
China, for example, has a large homogenous population for fast recruitment, an extensive hub of active investigators, a regulatory framework that aligns with that of US FDA regulations, and offers streamlined review and accelerated approval options.
Novotech Health Holdings is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, "Novotech" and "PPC". Novotech is a full-service clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. As of March 31, 2021, Novotech had a total of 1,765 FTEs working across our offices in 11 geographies in Asia-Pacific and the United States.
Dr. Jian Zhang has long been engaged in the standardized treatment and clinical research of breast cancer, as well as the phase I clinical research of solid tumors. He once studied at START, the world's largest phase I clinical center in TEXAS, USA. In 2015, he served as the review work for half a year in the Drug Evaluation Center of the National Food and Drug Administration (CFDA/NMPA) and was selected as the 1st batch of CFDA clinical part-time reviewers in the country. Dr. Zhang also Participated in the International Oncology Leading Investigator Training Program (I-LIT) program in 2015 and completed the Harvard University Global Clinical Scholar Research Training (GCSRT) international training program from 2019 to 2020 and is an honorary alumnus of Harvard University. Moreover, Dr. Zhang was selected into the 3rd batch of Fudan University "Zhuoxue Talent Program".
In her most recent role, Wenn is the Executive Chairman of Kinnate Biopharma China Joint Venture company. In 2018 Wenn founded PREMIA in collaboration with LCSCRUM leadership. Previously, Wenn was the Founder and Managing Partner for OxOnc Development, a venture company that, along with Pfizer Oncology, co-developed Xalkori in patients with ROS1 genetic alterations. Wenn was the head of Strategic Alliances for GSK Oncology, and helped build its alliances with various clinical research networks in the world. She was appointed the Chief Business Development officer at the Lurie Cancer Center of Northwestern University after her post-doctoral fellowship at the University of Wisconsin-Madison.
Mr. Andy Liu has strong operational experience in the CRO industry and a deep understanding of the regional market. Andy worked at Covance, Inc., a global CRO, for more than 10 years in a number of executive positions. Before joining PPC group, he was General Manager of Covance’s Central Laboratory Service, Asia Pacific, where he led a large multi-functional team of around 500 employees across multiple sites in APAC. Andy holds an MBA from the Booth School of Business at the University of Chicago, an MS in Electrical Engineering from the Rose-Hulman Institute of Technology, and a BS in Electrical Engineering from Tsinghua University.
Yan has 11 years of experience in pharmaceutical and CRO companies. She has served multiple roles across portfolio management, project management, clinical operations and clinical science at Eli Lily China, Merck Biopharma Japan, IQVIA Japan and Novartis Japan. Yan holds a Ph.D. in Immunology from the University of Tokyo, a Master’s Degree in Drug Delivery System, and a Bachelor’s Degree in Pharmaceutical Sciences from Kyoto University.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.